Changes within each group the patients in clinical outcomes at 6-month follow up Table 2 Intervention mean (SD) (n = 63) Comparison mean (SD) (n = 60) Clinical outcomes Baseline 6-month Change T p-value Baseline 6-month Change t p-value Follow up Follow up FBS (mg/dl) 149.27 132.67 -16.86 2.659 0.010* 134.17 167.62 32.58 -3.586 0.060 (43.35) (43.35) (46.08) (40.92) HbA1c (%) 8.65 6.82 -1.96 6.229 0.000* 8.42 9.03 0.49 -2.304 0.025 (1.42) (15.59) (1.42) (1.29) LDL (mg/dl) 123.78 115.98 -8.19 2.182 0.033** 121.55 134.97 13.03 -1.937 0.058 (19.36) (25.03) (33.22) (29.85) Systolic blood 119.83 120.71 0.85 -0.304 0.762 117.17 118.33 1.03 -0.166 0.868 (9.11) (20.75) (10.68) (31.87) pressure (mm.Hg.) Diastolic blood 77.62 77.71 0.06 -0.089 0.930 76.58 76.67 0.06 0.116 0.908 (6.73) (7.82) (6.86) (18.13) pressure (mm.Hg.) *p < 0.0001, **p < 0.05
Table 2 Changes within each group the patients in clinical outcomes at 6-month follow up Clinical outcomes Intervention mean (SD) (n = 63) Comparison mean (SD) (n = 60) Baseline 6-month Follow up Change T p-value Baseline 6-month Follow up Change t p-value FBS (mg/dl) 149.27 (43.35) 132.67 (43.35) -16.86 2.659 0.010* 134.17 (46.08) 167.62 (40.92) 32.58 -3.586 0.060 HbA1c (%) 8.65 (1.42) 6.82 (15.59) -1.96 6.229 0.000* 8.42 (1.42) 9.03 (1.29) 0.49 -2.304 0.025 LDL (mg/dl) 123.78 (19.36) 115.98 (25.03) -8.19 2.182 0.033** 121.55 (33.22) 134.97 (29.85) 13.03 -1.937 0.058 Systolic blood pressure (mm.Hg.) 119.83 (9.11) 120.71 (20.75) 0.85 -0.304 0.762 117.17 (10.68) 118.33 (31.87) 1.03 -0.166 0.868 Diastolic blood pressure (mm.Hg.) 77.62 (6.73) 77.71 (7.82) 0.06 -0.089 0.930 76.58 (6.86) 76.67 (18.13) 0.06 0.116 0.908 *p < 0.0001, **p < 0.05
F-5610036.docx